Extract

Phase I: To determine the dose of lenalidomide to be used in phase II part of the study. Phase II: To investigate the effect of an anti-inflammatory therapy consisting of lenalidomide in combination with pioglitazone, dexamethasone and metronomic low-dose chemotherapy with treosulfan on the response rate in patients with relapsed or refractory or progressive multiple myeloma in third-line

Inclusion criteria

• Multiple myeloma

Links

• ictrp
• euctr